Viyash Scientific Limited · NSE:VIYASH
Viyash Scientific — Q4 FY25 Earnings Presentation
37 slides from Viyash Scientific's earnings presentation, May 21, 2025
Slide 1: Proven Ability In Life Sciences - Exchange Intimation
Proven Ability In Life Sciences May 21, 2025 To, BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers, Exchange Plaza, Dalal Street, Fort, Bandra-Kurla Complex, Mumbai - 400 001 Bandra (East), Mumbai - 400 051 Scrip code: 512529 Scrip code: SEQUENT Subject: Press Release an
Slide 2: SeQuent growth continues to accelerate
SeQuent growth continues to accelerate Q4 FY25 – Revenues at ₹ 4,017 Million up by 11.2%, EBITDA at ₹ 569 Million up 38.7% FY25 – Revenues at ₹ 15,514 Million up by 13.3%, EBITDA at ₹ 1,993 Million up 86.6% Mumbai, May 20, 2025 SeQuent Scientific Limited (SeQuent), which has businesses across Animal
Slide 3: Earnings Call with Investors
Earnings Call with Investors The Company will conduct an Earnings call at 9:00 AM IST on May 21, 2025 where the Management will discuss the Company’s performance and answer questions from participants. To participate in this conference call, please dial the numbers provided below ten minutes ahead o
Slide 4: Investor Presentation Q4 FY25
INVESTOR PRESENTATION Q4 FY25 SEQUENT SCIENTIFIC LIMITED 20th May 2025
Slide 5: Steadfast Commitment to Improvement in Business Fundamentals
Steadfast Commitment to Improvement in Business Fundamentals “This quarter reinforces the momentum that we have built in the business over the last 18 months. The significant improvement in profitability metrics and double-digit revenue growth has come on the back of several initiatives which have h
Slide 6: SeQuent & Viyash: Proforma Q4FY25 Combined Performance
SeQuent & Viyash : Proforma Q4FY25 Combined Performance
Slide 7: Q4 FY25 Performance Highlights (Combined)
Q4 FY25 Performance Highlights (Combined) All values in ₹ Mn Net Debt to LTM Revenues Adj. EBITDA1 Adj. EBITDA margin Adj. EBITDA1 ₹7,725 ₹1,222 15.8% 1.0x Million Million 485 13.2% 63.2% vs. 1.2x YoY YoY bps in Q3FY25 YoY 4 Notes: 1. Viyash EBITDA is adjusted for one-time contractual bonus payable
Slide 8: FY25 Performance Highlights (Combined)
FY25 Performance Highlights (Combined) All values in ₹ Mn Net Debt to LTM Revenues Adj. EBITDA1 Adj. EBITDA margin Adj. EBITDA1 ₹30,094 ₹4,539 15.1% 1.0x Million Million 488 12.3% 65.7% vs. 1.2x YoY YoY bps in Q3FY25 YoY 5 Notes: 1. Viyash EBITDA is adjusted for ESOP costs, cost for accelerated vest
Slide 9: SeQuent: Q4FY25 Performance Update
SeQuent : Q4FY25 Performance Update
Slide 10: Strong profitable business growth continues in Q4FY25
Strong profitable business growth continues in Q4FY25All values in ₹ Mn Revenues Adj. EBITDA1 Adj. EBITDA margin PAT ₹4,017 ₹569 14.2% ₹103 Million Million Million 280 11.2% 38.7% 712% YoY YoY bps YoY YoY 7 Note: 1. EBITDA for SeQuent is adjusted for ESOP Costs
Slide 11: FY25: Closed the year with healthy double-digit profitable growth
FY25: Closed the year with healthy double-digit profitable growth All values in ₹ Mn Revenues Adj. EBITDA1 Adj. EBITDA margin Net Debt to LTM Adj. EBITDA1 ₹15,514 ₹1,993 12.8% 1.9x Million Million 505 vs. 13.3% 86.6% YoY YoY bps 3.5x YoY in FY24 8 Note: 1. EBITDA for SeQuent is adjusted for ESOP Cos
Slide 12: Revenue Performance – by Geography
Revenue Performance – by Geography All values in ₹ Mn Revenue Distribution Q4 FY25 Q3 FY25 Q4 FY24 YoY Gr% FY25 FY24 YoY Gr% Formulations 3,015 3,008 2,476 22% 11,858 9,997 19% Europe 1,323 1,334 1,236 7% 5,565 4,868 14% Emerging Markets 1,429 1,366 1,007 42% 5,138 4,091 26% India 263 308 232 13% 1,
Slide 13: SeQuent: Q4FY25 Business Performance
SeQuent: Q4FY25 Business Performance All values in ₹ Mn Europe: Vaccine opportunity proceeding well 1,000+ FDFs Emerging Markets: Resumption of Tablet sales Formulations LATAM: Initiated work on the nutraceutical solution range for 90+ commercialization Countries India: Ready for 2nd phase of field
Slide 14: SeQuent: FY25 Business Performance
SeQuent: FY25 Business Performance All values in ₹ Mn Europe: New product launches & vaccines distribution 1,000+ FDFs Emerging Markets: EUGMP renewal, volume recovery and timely price hikes Formulations LATAM: Focus on high margin business, new organisation in Mexico 90+ Countries India: Expanded f
Slide 15: Consolidated Financials
Consolidated Financials All values in ₹ Mn Q4 Q3 Grw QoQ Q4 Grw YoY Grw YoY Particulars FY25 FY24 FY25 FY25 % FY24 % % Revenue from Operations 4,017 3,908 2.8% 3,612 11.2% 15,514 13,697 13.3% Material Consumption (1,997) (2,025) (1,945) (8,119) (7,597) Gross Margin 2,020 1,883 7.3% 1,667 21.2% 7,3
Slide 16: Viyash: Business Update
Viyash Viyash: Business Update
Slide 17: Viyash: Q4FY25 – Continued Strong Performance on Revenue, Profitability and Cashflows
Viyash: Q4FY25 – Continued Strong Performance on Revenue, Profitability and Cashflows All values in ₹ Mn Net Debt to LTM Revenues Adj. EBITDA1 Adj. EBITDA margin Adj. EBITDA1 ₹3,708 ₹653 17.6% 0.3x Million Million 710 15.4% 93.2% vs.1.1x YoY YoY bps In FY24 YoY 14 Notes: 1. Viyash EBITDA is adjusted
Slide 18: Viyash: FY25 – Robust Full-year Performance
Viyash: FY25 – Robust Full-year Performance All values in ₹ Mn Net Debt to LTM Revenues Adj. EBITDA1 Adj. EBITDA margin Adj. EBITDA1 ₹14,580 ₹2,546 17.5% 0.3x Million Million 470 11.2% 52.4% vs.1.1x YoY YoY bps In FY24 YoY 15 Notes: 1. Viyash EBITDA is adjusted for ESOP costs, cost for accelerated v
Slide 19: Financial Performance
Financial Performance All values in ₹ Mn Q4 Q4 Q3 Particulars YoY % QoQ % FY25 FY242 YoY % FY25 FY24 FY25 Revenue from Operations 3,708 3,214 15.4% 3,839 -3.4% 14,580 13,110 11.2% Material Consumption (1,652) (1,420) 16.4% (1,751) -5.7% (6,608) (6,142) 7.6% Gross Profit 2,056 1,793 17.1% 2,088 1.5%
Slide 20: Key Updates from Q4FY25
Key Updates from Q4FY25 Facility Inspections Regulatory Approvals Launches 3 Regulatory Audits 6 APIs: USDMF (1), 3 API 28 Customer audits EDMF (3), CN (2) 1 FDFs Products Filed Validations Completed R&D Pipeline 03 APIs: USDMF (1), 3 API + 1 intermédiate 25+ Products CEP (1), EDMF(1) 17 Source: Viy
Slide 21: Viyash: Overview (3 key segments)
Viyash: Overview (3 key segments) APIs Strategic Innovator & CDMO Formulations ✓ 70+ commercial products; 23% CAGR for 10 products over FY22-25 with 58% material margins. Market leader for 6 of those products ✓ Portfolio: 23 commercial ANDAs ✓ 200+ customers across 150+ countries; ✓ Existing custome
Slide 22: Merger Update
Merger Update bo
Slide 23: Q4FY25: Combined Business Performance
Q4FY25: Combined Business Performance Q4 FY25 YoY Growth % SeQuent Combined (For the quarter) (Combined) Revenue 3,708 4,017 7,725 13.2% (INR Mn) Adj. EBITDA1 653 569 1,222 63.2% (INR Mn) Adj. EBITDA 17.6% 14.2% 15.8% +485bps Margin % Net Debt to LTM 0.3x 1.9x 1.0x Adj. EBITDA 20 Notes: 1. Viyash EB
Slide 24: FY25: Combined Business Performance
FY25: Combined Business Performance YoY Growth % FY25 SeQuent Combined (Combined) Revenue 12.3% 14,580 15,514 30,094 (INR Mn) Adj. EBITDA1 2,546 1,993 4,539 65.7% (INR Mn) Adj. EBITDA 17.5% 12.8% 15.1% +488bps Margin % Net Debt to LTM 0.3x 1.9x 1.0x Adj. EBITDA 21 Notes: 1. Viyash EBITDA is adjusted
Slide 25: Combined P&L – Snapshot
Combined P&L – Snapshot All values in ₹ Mn Viyash SeQuent Combined Particulars FY24 FY25 FY24 FY25 FY24 FY25 Key Notes : Revenue from Operations 13,110 14,580 13,697 15,514 26,807 30,094 Material Consumption (6,142) (6,608) (7,597) (8,119) (13,739) (14,727) ESOP cost, Exceptional items and amortizat
Slide 26: Combined Balance Sheet & Cash Flow: INR 2.5bn in Free Cash Generation in FY25
Combined Balance Sheet & Cash Flow: INR 2.5bn in Free Cash Generation in FY25 All values in ₹ Mn Combined Combined Balance Sheet Cash Flow FY24 FY25 FY24 FY25 Non-Current Assets 23,583 23,062 Adj. EBITDA 2,739 4,539 Fixed Assets 10,592 10,332 Less: NWC (1,207) (580) Goodwill 7,569 7,961 Less: Tax (4
Slide 27: Merger – Process Update
Merger – Process Update Merger process status update • CCI approval received • Stock exchange NOC process underway - scheme under review and final NOC awaited • Upon receipt of NOC, NCLT filing to be made • Other regulatory approvals, if any to follow Expected timelines for the completion of the mer
Slide 28: Synergy Update
Synergy Update 4 Core synergy areas identified Synergy Realization Timeline (Months) Synergy Planning Process on Track Till Merger Area Key Ideation Action Items 0-6 6-12 12+ ✓ CCI approval Approval received • R&D teams to be co-located; ✓ Senior management to work collaboratively on teams have iden
Slide 29: Group Strategy
Group Strategy bo
Slide 30: Key Pillars of our Strategy
Key Pillars of our Strategy Aspiration Build a unique, differentiated, global end-to-end integrated platform with leadership in animal and global pharmaceuticals 1 2 3 Strategic Global API++ Innovator and Formulations CDMO Management Team: Senior management team with deep domain experience and globa
Slide 31: API++: Key Differentiators
API++: Key Differentiators Products Customers & Markets Manufacturing Operating Backbone 200+ products in portfolio across animal Well diversified business with 175+ 14+ plants with FDA, EU GMP, ANVISA 200+ R&D resources; invested in & human health care. Basket of high customers across 150+ markets;
Slide 32: API++: Drivers of future growth
API++: Drivers of future growth Dimension Current State of Play Key growth levers • Developing oncology focused portfolio across all • Filed 31 products & validated 22 products in Portfolio OEBs FY25 • 35+ products in the pipeline; complex portfolio • Adding (i) spray drying capabilities in high pot
Slide 33: Global Formulations: Key Differentiators
Global Formulations: Key Differentiators Wide Portfolio Global Markets Leadership position Quality Manufacturing 1,000+ SKUs across multiple segments 300+ field force across 10 core markets Top 5 market position in focus 6 manufacturing facilities, across (gut health, pain management, segments acros
Slide 34: Global Formulations: Drivers of future growth
Global Formulations: Drivers of future growth Dimension Current State of Play Key Growth Levers • 1000+ SKUs across multiple species and delivery forms • Expand key brands globally (injectables, orals, supplements) • Opportunistic in-licensing and marketing Portfolio • Ready-to-market technical mate
Slide 35: Strategic Innovator and CDMO business
Strategic Innovator and CDMO business 1 Leverage Relationships Combined business has relationship with multiple Innovators & Complex Generic customers 4 2 Acquisitions Invest in Operating Acquire capabilities to accelerate growth; Net Debt / Combined Adj. EBITDA <1x Capabilities 4 Key Levers to Crea
Slide 36: For details, feel free to contact
For details, feel free to contact: Yoshita Vora Abhishek Singhal Company Secretary Investor Relations Consultant +91 22 4111 4777 abhishek@arunya.co.in investorrelations@sequent.in Registered Office: 3rd Floor, Srivalli’s Corporate, Plot No. 290, SYN 33 34P TO 39, Guttala Begumpet, Jubilee Hills, Sh
Slide 37: Thank You
Thank You